View Future GrowthElixinol Wellness 過去の業績過去 基準チェック /06Elixinol Wellnessは64.4%の年平均成長率で業績を伸ばしているが、Personal Products業界はgrowingで10.5%毎年増加している。売上は成長しており、年平均8%の割合である。主要情報64.45%収益成長率83.11%EPS成長率Personal Products 業界の成長8.70%収益成長率8.04%株主資本利益率-73.81%ネット・マージン-35.48%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Mar 01Full year 2023 earnings released: AU$0.016 loss per share (vs AU$0.033 loss in FY 2022)Full year 2023 results: AU$0.016 loss per share (improved from AU$0.033 loss in FY 2022). Revenue: AU$9.05m (up 28% from FY 2022). Net loss: AU$7.51m (loss narrowed 29% from FY 2022).Reported Earnings • Sep 04First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.023 loss in 1H 2022)First half 2023 results: AU$0.009 loss per share (improved from AU$0.023 loss in 1H 2022). Revenue: AU$3.46m (up 7.4% from 1H 2022). Net loss: AU$3.40m (loss narrowed 52% from 1H 2022). Revenue is forecast to grow 39% p.a. on average during the next 2 years, compared to a 5.1% growth forecast for the Personal Products industry in Europe.Reported Earnings • Mar 03Full year 2022 earnings released: AU$0.033 loss per share (vs AU$0.054 loss in FY 2021)Full year 2022 results: AU$0.033 loss per share (improved from AU$0.054 loss in FY 2021). Revenue: AU$7.58m (down 19% from FY 2021). Net loss: AU$10.6m (loss narrowed 38% from FY 2021). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 31First half 2022 earnings released: AU$0.023 loss per share (vs AU$0.035 loss in 1H 2021)First half 2022 results: AU$0.023 loss per share (up from AU$0.035 loss in 1H 2021). Revenue: AU$3.34m (down 30% from 1H 2021). Net loss: AU$7.13m (loss narrowed 34% from 1H 2021).Reported Earnings • Feb 26Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: AU$0.054 loss per share (up from AU$0.58 loss in FY 2020). Revenue: AU$11.8m (down 21% from FY 2020). Net loss: AU$17.0m (loss narrowed 84% from FY 2020). Revenue exceeded analyst estimates by 36%.Reported Earnings • Aug 22First half 2021 earnings released: AU$0.035 loss per share (vs AU$0.60 loss in 1H 2020)The company reported a decent first half result with reduced losses and improved control over expenses, although revenues were weaker. First half 2021 results: Revenue: AU$4.79m (down 39% from 1H 2020). Net loss: AU$10.8m (loss narrowed 88% from 1H 2020).すべての更新を表示Recent updatesBoard Change • May 20High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Pauline Gately is the most experienced director on the board, commencing their role in 2023. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Mar 31Elixinol Wellness Limited, Annual General Meeting, May 27, 2026Elixinol Wellness Limited, Annual General Meeting, May 27, 2026.お知らせ • Sep 08Elixinol Wellness Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.Elixinol Wellness Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 46,800,000 Price\Range: AUD 0.0135 Discount Per Security: AUD 0.00081 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 138,385,185 Price\Range: AUD 0.0135 Discount Per Security: AUD 0.00081 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Jun 20+ 1 more updateElixinol Wellness Limited Announces Appointment of Natalie Butler as Chief Executive Officer, Effective June 19, 2025Elixinol Wellness Limited announced key executive appointments that strengthen the Company's leadership team and position Elixinol for growth. The Board has appointed Executive Director, Natalie Butler, as Chief Executive Officer (CEO), effective 19 June 2025. Natalie has been instrumental in leading the Company since stepping into an expanded executive role following the departure of the previous CEO in 2024. Natalie will remain a Director. Her remuneration arrangements will also remain unchanged, the details of which are provided within the Remuneration Report of the 2024 Annual Report. Natalie brings over a decade of leadership and commercial experience across the wellness and consumer sectors, with a track record of scaling high-growth businesses and building brands. Her deep understanding of Elixinol's operations, clear strategic vision, and strong executional discipline make her ideally placed to lead the Company's next phase.お知らせ • Jun 04Elixinol Wellness Limited has completed a Follow-on Equity Offering in the amount of AUD 0.15 million.Elixinol Wellness Limited has completed a Follow-on Equity Offering in the amount of AUD 0.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,571,429 Price\Range: AUD 0.0175 Discount Per Security: AUD 0.00105 Transaction Features: Subsequent Direct Listingお知らせ • May 21Elixinol Wellness Limited has filed a Follow-on Equity Offering.Elixinol Wellness Limited has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: Subsequent Direct Listingお知らせ • Mar 19Elixinol Wellness Limited, Annual General Meeting, May 20, 2025Elixinol Wellness Limited, Annual General Meeting, May 20, 2025.お知らせ • Oct 28Elixinol Wellness Limited Announces Resignation of Tai Phan as Joint Company Secretary, Effective 25 October 2024Elixinol Wellness Limited announced that Mr. Tai Phan has resigned as Joint Company Secretary, effective 25 October 2024. Ms. Melanie Leydin continues in the role of Company Secretary and, for the purposes of ASX Listing Rule 12.6, remains the primary person responsible for communication between the Company and the ASX.お知らせ • Apr 03Elixinol Wellness Limited, Annual General Meeting, May 30, 2024Elixinol Wellness Limited, Annual General Meeting, May 30, 2024.お知らせ • Mar 28Elixinol Wellness Limited (ASX:EXL) completed the acquisition of Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF).Elixinol Wellness Limited (ASX:EXL) entered into Conditional agreement to acquire Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF) for AUD 3 million on February 12, 2024. Under the terms of agreement, Elixinol Wellness will pay AUD 2 million as upfront payment and AUD 1 million as earnout consideration. Elixinol Wellness Limited will raise AUD 3.16 million through Rights Issue Offer which will be used in part to finance the acquisition. The deal is expected to be completed by the end of March, 2024. Completion of the Ananda Food acquisition is conditional on raising sufficient funds under the Rights Issue Offer and the satisfaction of a number of customary conditions. As of March 20, 2024, the transaction is expected to close on March 28, 2024. Elixinol Wellness Limited (ASX:EXL) completed the acquisition of Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF) on March 28, 2024. Ron Dufficy will now be stepping down from the role of Group Chief Executive Officer and Natalie Butler will join the EXL Board.Reported Earnings • Mar 01Full year 2023 earnings released: AU$0.016 loss per share (vs AU$0.033 loss in FY 2022)Full year 2023 results: AU$0.016 loss per share (improved from AU$0.033 loss in FY 2022). Revenue: AU$9.05m (up 28% from FY 2022). Net loss: AU$7.51m (loss narrowed 29% from FY 2022).お知らせ • Feb 14Elixinol Wellness Limited (ASX:EXL) entered into Conditional agreement to acquire Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF) for AUD 3 million.Elixinol Wellness Limited (ASX:EXL) entered into Conditional agreement to acquire Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF) for AUD 3 million on February 12, 2024. The deal is expected to be completed by the end of March, 2024.Board Change • Oct 10Less than half of directors are independentThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Non-Executive Director Dave Fenlon is the most experienced director on the board, commencing their role in 2022. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Reported Earnings • Sep 04First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.023 loss in 1H 2022)First half 2023 results: AU$0.009 loss per share (improved from AU$0.023 loss in 1H 2022). Revenue: AU$3.46m (up 7.4% from 1H 2022). Net loss: AU$3.40m (loss narrowed 52% from 1H 2022). Revenue is forecast to grow 39% p.a. on average during the next 2 years, compared to a 5.1% growth forecast for the Personal Products industry in Europe.New Risk • Sep 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 98% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.4m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Shareholders have been substantially diluted in the past year (98% increase in shares outstanding). Market cap is less than US$10m (€3.37m market cap, or US$3.63m). Minor Risks Currently unprofitable and not forecast to become profitable next year (AU$4.7m net loss next year). Revenue is less than US$5m (AU$7.6m revenue, or US$4.9m).New Risk • Aug 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$8.2m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Market cap is less than US$10m (€3.05m market cap, or US$3.33m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (AU$3.6m net loss in 2 years). Shareholders have been diluted in the past year (47% increase in shares outstanding). Revenue is less than US$5m (AU$7.1m revenue, or US$4.6m).お知らせ • May 24Elixinol Wellness Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.Elixinol Wellness Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 55,555,555 Price\Range: AUD 0.018 Discount Per Security: AUD 0.00108 Security Features: Attached Optionsお知らせ • May 23Elixinol Wellness Limited Announces Company Secretary ChangesElixinol Wellness Limited advised that Ms. Teresa Cleary has resigned as Company Secretary of Elixinol Wellness, effective immediately. The Board would like to take this opportunity to thank Ms Cleary for her outstanding contribution to the Company over the last three and half years and genuinely wishes her well with her future endeavours. Ms Josephine Lorenz, the Company's Group Chief Financial Officer, has been appointed as Joint Company Secretary, effective immediately. Ms Sarah Prince, Joint Company Secretary and Ms Lorenz are the persons responsible for communications with the ASX in relation to ASX Listing Rule matters.Reported Earnings • Mar 03Full year 2022 earnings released: AU$0.033 loss per share (vs AU$0.054 loss in FY 2021)Full year 2022 results: AU$0.033 loss per share (improved from AU$0.054 loss in FY 2021). Revenue: AU$7.58m (down 19% from FY 2021). Net loss: AU$10.6m (loss narrowed 38% from FY 2021). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 31First half 2022 earnings released: AU$0.023 loss per share (vs AU$0.035 loss in 1H 2021)First half 2022 results: AU$0.023 loss per share (up from AU$0.035 loss in 1H 2021). Revenue: AU$3.34m (down 30% from 1H 2021). Net loss: AU$7.13m (loss narrowed 34% from 1H 2021).Reported Earnings • Feb 26Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: AU$0.054 loss per share (up from AU$0.58 loss in FY 2020). Revenue: AU$11.8m (down 21% from FY 2020). Net loss: AU$17.0m (loss narrowed 84% from FY 2020). Revenue exceeded analyst estimates by 36%.Reported Earnings • Aug 22First half 2021 earnings released: AU$0.035 loss per share (vs AU$0.60 loss in 1H 2020)The company reported a decent first half result with reduced losses and improved control over expenses, although revenues were weaker. First half 2021 results: Revenue: AU$4.79m (down 39% from 1H 2020). Net loss: AU$10.8m (loss narrowed 88% from 1H 2020).Reported Earnings • Feb 28Full year 2020 earnings released: AU$0.58 loss per share (vs AU$0.50 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: AU$14.3m (down 47% from FY 2019). Net loss: AU$104.5m (loss widened 59% from FY 2019).収支内訳Elixinol Wellness の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:E8M 収益、費用、利益 ( )AUD Millions日付収益収益G+A経費研究開発費31 Dec 2516-510030 Sep 2516-410030 Jun 2516-29031 Mar 2515-29031 Dec 2415-29030 Sep 2413-49030 Jun 2412-79031 Mar 2410-79031 Dec 238-89030 Sep 238-710030 Jun 237-710031 Mar 237-911031 Dec 227-1113030 Sep 227-1214030 Jun 228-1316031 Mar 229-1517031 Dec 219-1719030 Sep 2111-2120030 Jun 2112-2522031 Mar 2113-6525031 Dec 2015-10529030 Jun 2021-16137031 Mar 2026-12138031 Dec 1931-8039030 Jun 1935-1029031 Mar 1934-523031 Dec 18320170質の高い収益: E8Mは現在利益が出ていません。利益率の向上: E8Mは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: E8Mは利益を出していないが、過去 5 年間で年間64.4%の割合で損失を削減してきた。成長の加速: E8Mの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: E8Mは利益が出ていないため、過去 1 年間の収益成長をPersonal Products業界 ( 5.6% ) と比較することは困難です。株主資本利益率高いROE: E8Mは現在利益が出ていないため、自己資本利益率 ( -73.81% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHousehold 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/11 14:55終値2026/08/11 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Elixinol Wellness Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関John HesterBell PotterSiddharth RajeevFundamental Research Corp.
Reported Earnings • Mar 01Full year 2023 earnings released: AU$0.016 loss per share (vs AU$0.033 loss in FY 2022)Full year 2023 results: AU$0.016 loss per share (improved from AU$0.033 loss in FY 2022). Revenue: AU$9.05m (up 28% from FY 2022). Net loss: AU$7.51m (loss narrowed 29% from FY 2022).
Reported Earnings • Sep 04First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.023 loss in 1H 2022)First half 2023 results: AU$0.009 loss per share (improved from AU$0.023 loss in 1H 2022). Revenue: AU$3.46m (up 7.4% from 1H 2022). Net loss: AU$3.40m (loss narrowed 52% from 1H 2022). Revenue is forecast to grow 39% p.a. on average during the next 2 years, compared to a 5.1% growth forecast for the Personal Products industry in Europe.
Reported Earnings • Mar 03Full year 2022 earnings released: AU$0.033 loss per share (vs AU$0.054 loss in FY 2021)Full year 2022 results: AU$0.033 loss per share (improved from AU$0.054 loss in FY 2021). Revenue: AU$7.58m (down 19% from FY 2021). Net loss: AU$10.6m (loss narrowed 38% from FY 2021). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 31First half 2022 earnings released: AU$0.023 loss per share (vs AU$0.035 loss in 1H 2021)First half 2022 results: AU$0.023 loss per share (up from AU$0.035 loss in 1H 2021). Revenue: AU$3.34m (down 30% from 1H 2021). Net loss: AU$7.13m (loss narrowed 34% from 1H 2021).
Reported Earnings • Feb 26Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: AU$0.054 loss per share (up from AU$0.58 loss in FY 2020). Revenue: AU$11.8m (down 21% from FY 2020). Net loss: AU$17.0m (loss narrowed 84% from FY 2020). Revenue exceeded analyst estimates by 36%.
Reported Earnings • Aug 22First half 2021 earnings released: AU$0.035 loss per share (vs AU$0.60 loss in 1H 2020)The company reported a decent first half result with reduced losses and improved control over expenses, although revenues were weaker. First half 2021 results: Revenue: AU$4.79m (down 39% from 1H 2020). Net loss: AU$10.8m (loss narrowed 88% from 1H 2020).
Board Change • May 20High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Pauline Gately is the most experienced director on the board, commencing their role in 2023. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 31Elixinol Wellness Limited, Annual General Meeting, May 27, 2026Elixinol Wellness Limited, Annual General Meeting, May 27, 2026.
お知らせ • Sep 08Elixinol Wellness Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.Elixinol Wellness Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 46,800,000 Price\Range: AUD 0.0135 Discount Per Security: AUD 0.00081 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 138,385,185 Price\Range: AUD 0.0135 Discount Per Security: AUD 0.00081 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Jun 20+ 1 more updateElixinol Wellness Limited Announces Appointment of Natalie Butler as Chief Executive Officer, Effective June 19, 2025Elixinol Wellness Limited announced key executive appointments that strengthen the Company's leadership team and position Elixinol for growth. The Board has appointed Executive Director, Natalie Butler, as Chief Executive Officer (CEO), effective 19 June 2025. Natalie has been instrumental in leading the Company since stepping into an expanded executive role following the departure of the previous CEO in 2024. Natalie will remain a Director. Her remuneration arrangements will also remain unchanged, the details of which are provided within the Remuneration Report of the 2024 Annual Report. Natalie brings over a decade of leadership and commercial experience across the wellness and consumer sectors, with a track record of scaling high-growth businesses and building brands. Her deep understanding of Elixinol's operations, clear strategic vision, and strong executional discipline make her ideally placed to lead the Company's next phase.
お知らせ • Jun 04Elixinol Wellness Limited has completed a Follow-on Equity Offering in the amount of AUD 0.15 million.Elixinol Wellness Limited has completed a Follow-on Equity Offering in the amount of AUD 0.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,571,429 Price\Range: AUD 0.0175 Discount Per Security: AUD 0.00105 Transaction Features: Subsequent Direct Listing
お知らせ • May 21Elixinol Wellness Limited has filed a Follow-on Equity Offering.Elixinol Wellness Limited has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: Subsequent Direct Listing
お知らせ • Mar 19Elixinol Wellness Limited, Annual General Meeting, May 20, 2025Elixinol Wellness Limited, Annual General Meeting, May 20, 2025.
お知らせ • Oct 28Elixinol Wellness Limited Announces Resignation of Tai Phan as Joint Company Secretary, Effective 25 October 2024Elixinol Wellness Limited announced that Mr. Tai Phan has resigned as Joint Company Secretary, effective 25 October 2024. Ms. Melanie Leydin continues in the role of Company Secretary and, for the purposes of ASX Listing Rule 12.6, remains the primary person responsible for communication between the Company and the ASX.
お知らせ • Apr 03Elixinol Wellness Limited, Annual General Meeting, May 30, 2024Elixinol Wellness Limited, Annual General Meeting, May 30, 2024.
お知らせ • Mar 28Elixinol Wellness Limited (ASX:EXL) completed the acquisition of Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF).Elixinol Wellness Limited (ASX:EXL) entered into Conditional agreement to acquire Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF) for AUD 3 million on February 12, 2024. Under the terms of agreement, Elixinol Wellness will pay AUD 2 million as upfront payment and AUD 1 million as earnout consideration. Elixinol Wellness Limited will raise AUD 3.16 million through Rights Issue Offer which will be used in part to finance the acquisition. The deal is expected to be completed by the end of March, 2024. Completion of the Ananda Food acquisition is conditional on raising sufficient funds under the Rights Issue Offer and the satisfaction of a number of customary conditions. As of March 20, 2024, the transaction is expected to close on March 28, 2024. Elixinol Wellness Limited (ASX:EXL) completed the acquisition of Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF) on March 28, 2024. Ron Dufficy will now be stepping down from the role of Group Chief Executive Officer and Natalie Butler will join the EXL Board.
Reported Earnings • Mar 01Full year 2023 earnings released: AU$0.016 loss per share (vs AU$0.033 loss in FY 2022)Full year 2023 results: AU$0.016 loss per share (improved from AU$0.033 loss in FY 2022). Revenue: AU$9.05m (up 28% from FY 2022). Net loss: AU$7.51m (loss narrowed 29% from FY 2022).
お知らせ • Feb 14Elixinol Wellness Limited (ASX:EXL) entered into Conditional agreement to acquire Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF) for AUD 3 million.Elixinol Wellness Limited (ASX:EXL) entered into Conditional agreement to acquire Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF) for AUD 3 million on February 12, 2024. The deal is expected to be completed by the end of March, 2024.
Board Change • Oct 10Less than half of directors are independentThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Non-Executive Director Dave Fenlon is the most experienced director on the board, commencing their role in 2022. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Reported Earnings • Sep 04First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.023 loss in 1H 2022)First half 2023 results: AU$0.009 loss per share (improved from AU$0.023 loss in 1H 2022). Revenue: AU$3.46m (up 7.4% from 1H 2022). Net loss: AU$3.40m (loss narrowed 52% from 1H 2022). Revenue is forecast to grow 39% p.a. on average during the next 2 years, compared to a 5.1% growth forecast for the Personal Products industry in Europe.
New Risk • Sep 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 98% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.4m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Shareholders have been substantially diluted in the past year (98% increase in shares outstanding). Market cap is less than US$10m (€3.37m market cap, or US$3.63m). Minor Risks Currently unprofitable and not forecast to become profitable next year (AU$4.7m net loss next year). Revenue is less than US$5m (AU$7.6m revenue, or US$4.9m).
New Risk • Aug 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$8.2m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Market cap is less than US$10m (€3.05m market cap, or US$3.33m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (AU$3.6m net loss in 2 years). Shareholders have been diluted in the past year (47% increase in shares outstanding). Revenue is less than US$5m (AU$7.1m revenue, or US$4.6m).
お知らせ • May 24Elixinol Wellness Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.Elixinol Wellness Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 55,555,555 Price\Range: AUD 0.018 Discount Per Security: AUD 0.00108 Security Features: Attached Options
お知らせ • May 23Elixinol Wellness Limited Announces Company Secretary ChangesElixinol Wellness Limited advised that Ms. Teresa Cleary has resigned as Company Secretary of Elixinol Wellness, effective immediately. The Board would like to take this opportunity to thank Ms Cleary for her outstanding contribution to the Company over the last three and half years and genuinely wishes her well with her future endeavours. Ms Josephine Lorenz, the Company's Group Chief Financial Officer, has been appointed as Joint Company Secretary, effective immediately. Ms Sarah Prince, Joint Company Secretary and Ms Lorenz are the persons responsible for communications with the ASX in relation to ASX Listing Rule matters.
Reported Earnings • Mar 03Full year 2022 earnings released: AU$0.033 loss per share (vs AU$0.054 loss in FY 2021)Full year 2022 results: AU$0.033 loss per share (improved from AU$0.054 loss in FY 2021). Revenue: AU$7.58m (down 19% from FY 2021). Net loss: AU$10.6m (loss narrowed 38% from FY 2021). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 31First half 2022 earnings released: AU$0.023 loss per share (vs AU$0.035 loss in 1H 2021)First half 2022 results: AU$0.023 loss per share (up from AU$0.035 loss in 1H 2021). Revenue: AU$3.34m (down 30% from 1H 2021). Net loss: AU$7.13m (loss narrowed 34% from 1H 2021).
Reported Earnings • Feb 26Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: AU$0.054 loss per share (up from AU$0.58 loss in FY 2020). Revenue: AU$11.8m (down 21% from FY 2020). Net loss: AU$17.0m (loss narrowed 84% from FY 2020). Revenue exceeded analyst estimates by 36%.
Reported Earnings • Aug 22First half 2021 earnings released: AU$0.035 loss per share (vs AU$0.60 loss in 1H 2020)The company reported a decent first half result with reduced losses and improved control over expenses, although revenues were weaker. First half 2021 results: Revenue: AU$4.79m (down 39% from 1H 2020). Net loss: AU$10.8m (loss narrowed 88% from 1H 2020).
Reported Earnings • Feb 28Full year 2020 earnings released: AU$0.58 loss per share (vs AU$0.50 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: AU$14.3m (down 47% from FY 2019). Net loss: AU$104.5m (loss widened 59% from FY 2019).